Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06763640 | Prognostic Value of TIL in Nasopharyngeal Carcinoma | enrolling by invitation | — | 216 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05377736 | Thyroid Nodule Gene Sequencing in a Danish Population | active not recruiting | N/A | 30 | Aarhus University HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06759155 |
| Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma |
| not yet recruiting |
| Phase 2 |
| 20 |
| University of Vermont Medical CenterOTHER |
| 0 |
| Jan 6, 2025 |
| clinicaltrials |
| NCT06725576 | Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma | recruiting | — | 201 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05869227 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 166 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06414577 | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | active not recruiting | Phase 2 | 38 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752382 | Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC | not yet recruiting | Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752473 | KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 10 | Kousai Bio Co., Ltd.OTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06733948 | ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05668962 | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730529 | The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730971 | This Study is Mainly About Finding Incidence Among Other Factors of Thyroid Cancer in Patient with Benign Disease As MNG to Early Discover of the Malignancy to Save the Patient from Aggressive Procedure | not yet recruiting | — | 300 | Asmaa Mohamed EmamOTHER | 0 | Dec 12, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06725628 | Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma | not yet recruiting | — | 2,000 | Tianhan ZhouOTHER_GOV | 0 | Dec 10, 2024 | clinicaltrials |
| NCT06236373 | The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia(Survivorship) | recruiting | — | 45 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06482086 | Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | recruiting | Phase 2 | 75 | West China HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06713057 | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer | not yet recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03813394 | Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC(2018/00947) | active not recruiting | Phase 1 / Phase 2 | 48 | National University Hospital, SingaporeOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06695936 | Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinoma Patients: a Prospective Cohort Study | not yet recruiting | — | 329 | Sun Yat-sen UniversityOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06688760 | Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma | recruiting | N/A | 86 | Ming-Yuan ChenOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06380686 | Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome(HEAT) | recruiting | — | 120 | AIO-Studien-gGmbHOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06680115 | Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 150 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06675214 | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. | recruiting | Phase 3 | 586 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05424692 | Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer | recruiting | N/A | 200 | Peking Union Medical College HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06583395 | Quest to Analyze One Thousand Humans Meditating(QUANTUM) | enrolling by invitation | — | 3,000 | Tobias Moeller-BertramINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06664983 | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06149637 | Lateral Cervical Node Dissection in Differentiated Thyroid Cancer. | recruiting | N/A | 62 | Centro de Excelencia en Enfermedades de Cabeza y CuelloOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06662929 | Arabic PRO Measures for Head and Neck Cancer Radiotherapy.(PROMs) | recruiting | — | 125 | King Saud UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06572293 | Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma | not yet recruiting | N/A | 250 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 16, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05766098 | Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY(PTC-ARRAY) | recruiting | — | 600 | Istituto Auxologico ItalianoOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06626581 | Iodine Status and Characteristics of Papillary Thyroid Cancer | not yet recruiting | — | 600 | Shandong Provincial HospitalOTHER_GOV | 0 | Oct 4, 2024 | clinicaltrials |
| NCT06627998 | Study of the Prevalence of Osteo-metabolic Complications in Patients With Thyroid Cancer | recruiting | — | 82 | IRCCS San RaffaeleOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06623500 | Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer | recruiting | — | 1,600 | Shandong Provincial HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06463392 | Deep Learning-based sbORN Diagnostic Model | recruiting | — | 312 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06592755 | Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC | recruiting | — | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06611150 | Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma | recruiting | Phase 1 | 24 | Sun Yat-sen UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06611137 | SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06614686 | U87 CAR-T in Patients With Advanced Head and Neck Tumors | recruiting | Phase 1 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06611826 | GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | not yet recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06612697 | Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone | active not recruiting | — | 262 | Taichung Veterans General HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04498221 | Lymphatic Mapping Of Oropharyngeal Cancer(LOOC) | recruiting | N/A | 150 | University College, LondonOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04970134 | Spanish Study for Molecular Characterization of Thyroid Carcinoma(MOLTHY) | active not recruiting | — | 150 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05517135 | tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella) | recruiting | — | 1,000 | National Cancer Centre, SingaporeOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589609 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | recruiting | Phase 1 | 12 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jan 9, 2025source: clinicaltrials